The Importance of Quality of Life Assessment

Charles R. Thomas Jr, MD, PhD

Dose escalation of an antineoplastic modality such as radiotherapy (RT) may result in an increased therapeutic ratio with the use of effective strategies to mitigate normal tissue toxic effects. Successful execution of dose escalation using external beam RT (EBRT) approaches has yielded unintended outcomes. While increased disease control and survival are a focus of such strategies to increase the therapeutic ratio, quality of life (QOL), as measured by appropriate patient-related outcomes tools, are nearly as important. To that end, Movsas et al, in this issue of JAMA Oncology, document that an attempt to deliver nearly a quarter higher total dose (74 Gy vs 60 Gy) of EBRT given concomitantly with a platinum-taxane doublet for locally advanced non–small-cell lung cancer (LA-NSCLC) results in a clinically meaningful decrement in QOL at 3 months.

However, the Radiation Therapy Oncology Group 0617 trial is not the definitive treatise regarding the RT dose-escalation question for LA-NSCLC. The QOL assessments, as well as the survival results, likely were influenced by numerous factors that are difficult to control for in a multi-institutional, cooperative group clinical trial setting. Emerging data on molecular signatures that may predict radiosensitivity and/or radioresistance of tumor, as well as normal tissue, may be helpful in future assessment of baseline patient characteristics for those enrolled in prospective, large-scale cancer clinical trials of RT-based treatment. Moreover, not all modes of potential RT delivery and dose escalation are equal. Currently, radiation oncologists see patients on a weekly basis and basically assess symptoms as a “snapshot in time.” This is fraught with recall bias and other factors that contribute to a diminished appreciation of real-time patient-related outcomes, which should ideally be recorded on a continuous 24/7 basis to assess QOL during treatment. Movsas and colleagues are to be congratulated for executing a trial that will help in the design of next-generation QOL trials for LA-NSCLC.
Dose Escalation in Stage III Non–Small-Cell Lung Cancer Patients Agree With the Clinical Results

David Cella, PhD

As we conduct clinical research to continue to “move the dial” of progress against lung cancer, it has become increasingly important to consider the patient’s perspective alongside that of more standard efficacy and safety end points. Besides the obvious reason of patient centrality, there are several compelling clinical reasons to do so. In this issue of *JAMA Oncology*, the article by Movsas and colleagues provides us with more evidence to illustrate the importance of the patient’s perspective on efficacy and safety in clinical trials, and especially the importance of studies in advanced disease. The results reaffirm a few principles of quality-of-life measurement in advanced tumor oncology that can now be considered teachable facts, supported by robust results, reproduced in multiple studies, using various questionnaires. Three such facts are (1) quality-of-life reports taken at the start of a new therapy for advanced disease are predictive of survival; (2) clinician-rated toxicity on the Common Terminology Criteria for Adverse Events (CTCAE) grading system underestimates the adverse effects of treatments on patients’ lives; and (3) dose escalation, whether chemotherapeutic or radiotherapeutic, has predictable, deleterious effects on quality of life, as reported on a well-validated lung cancer questionnaire. To frame these “facts,” I will discuss them in the context of the article by Movsas et al.

Despite promising phase 2 trial data in patients with unresectable stage III non–small-cell lung cancer (NSCLC), escalating dose of radiation therapy (RT) and adding cetuximab did not lengthen survival when compared with standard dose RT with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol*. 2015;16(2):187-199.


**Influenced by the article by Movsas and colleagues**, I will discuss the following three facts, supported by robust results, reproduced in multiple studies, using various questionnaires. Three such facts are (1) quality-of-life reports taken at the start of a new therapy for advanced disease are predictive of survival; (2) clinician-rated toxicity on the Common Terminology Criteria for Adverse Events (CTCAE) grading system underestimates the adverse effects of treatments on patients’ lives; and (3) dose escalation, whether chemotherapeutic or radiotherapeutic, has predictable, deleterious effects on quality of life, as reported on a well-validated lung cancer questionnaire. To frame these “facts,” I will discuss them in the context of the article by Movsas et al.

Despite promising phase 2 trial data in patients with unresectable stage III non–small-cell lung cancer (NSCLC), escalating dose of radiation therapy (RT) and adding cetuximab did not lengthen survival when compared with standard dose RT with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol*. 2015;16(2):187-199.

